AB CHFUPYCA

AB-CHFUPYCA (also AB-CHMFUPPYCA) is a compound that was first identified as a component of synthetic cannabis products in Japan in 2015. The name "AB-CHFUPYCA" is an acronym of its systematic name N-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(CycloHexylmethyl)-3-(4-FlUorophenyl)-1H-PYrazole-5-CarboxAmide.

Although AB-CHFUPYCA contains structural elements common to the synthetic cannabinoid designer drugs AB-PINACA and AB-FUBINACA, it can also be considered an analog of the traditional pyrazole cannabinoid receptor 1 antagonist rimonabant. Its pharmacological properties have been the subject of only very limited study; it is presumed to be a potent agonist of the CB₁ receptor.